Exact Sciences‘ Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients, the company announced today.

The results of the study–which included 299 intermediate-risk patients, with 175 of them classified as UFI-risk–showed that UFI-risk patients with a GPS test result greater than 40 had outcomes consistent with the high-risk disease and a poor prognosis. Meanwhile, those patients with a GPS value less than 40 had outcomes similar to favorable intermediate-risk patients.

These findings were published in Urology.

Genomic Health, which was acquired by Exact Sciences in 2019, developed the GPS test.